IRIS
RISITANO, ANTONIO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.146
NA - Nord America 4.998
EU - Europa 3.386
SA - Sud America 899
AF - Africa 154
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.593
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.706
SG - Singapore 2.750
RU - Federazione Russa 1.784
VN - Vietnam 1.184
CN - Cina 1.018
BR - Brasile 713
HK - Hong Kong 564
IT - Italia 470
FR - Francia 266
CA - Canada 165
DE - Germania 163
FI - Finlandia 146
NL - Olanda 134
IN - India 102
JP - Giappone 96
GB - Regno Unito 94
IE - Irlanda 94
BD - Bangladesh 93
AR - Argentina 78
MX - Messico 68
UA - Ucraina 61
IQ - Iraq 47
KR - Corea 44
SE - Svezia 44
CI - Costa d'Avorio 38
ZA - Sudafrica 36
PH - Filippine 35
ID - Indonesia 33
EC - Ecuador 32
AT - Austria 26
TH - Thailandia 24
PK - Pakistan 22
TR - Turchia 18
ES - Italia 17
PL - Polonia 17
CL - Cile 16
CO - Colombia 16
LT - Lituania 15
KE - Kenya 13
SA - Arabia Saudita 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 11
PY - Paraguay 11
AZ - Azerbaigian 10
EG - Egitto 10
TW - Taiwan 10
CR - Costa Rica 9
DO - Repubblica Dominicana 9
UZ - Uzbekistan 9
IL - Israele 8
BE - Belgio 7
DZ - Algeria 7
HN - Honduras 7
MA - Marocco 7
NG - Nigeria 7
NP - Nepal 7
PE - Perù 7
PS - Palestinian Territory 7
TN - Tunisia 7
UY - Uruguay 7
ET - Etiopia 6
JM - Giamaica 6
JO - Giordania 6
LY - Libia 6
AU - Australia 5
BO - Bolivia 5
CH - Svizzera 5
CZ - Repubblica Ceca 5
HR - Croazia 5
KZ - Kazakistan 5
PA - Panama 5
TT - Trinidad e Tobago 5
AL - Albania 4
CY - Cipro 4
IR - Iran 4
LV - Lettonia 4
MY - Malesia 4
BS - Bahamas 3
BY - Bielorussia 3
EU - Europa 3
OM - Oman 3
PR - Porto Rico 3
QA - Qatar 3
RO - Romania 3
SV - El Salvador 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BZ - Belize 2
GE - Georgia 2
GR - Grecia 2
KW - Kuwait 2
LB - Libano 2
LU - Lussemburgo 2
MU - Mauritius 2
NI - Nicaragua 2
NO - Norvegia 2
PT - Portogallo 2
RS - Serbia 2
SO - Somalia 2
Totale 15.563
Salva come PNG Salva come JPEG
Città #
Singapore 1.178
San Jose 779
Hong Kong 538
Moscow 446
Chandler 346
Ashburn 325
Ho Chi Minh City 325
Hanoi 243
Beijing 240
The Dalles 215
Santa Clara 174
Millbury 171
Lauterbourg 169
Boston 135
Princeton 133
Los Angeles 132
Nanjing 128
Des Moines 117
New York 110
Hefei 108
Amsterdam 104
Ottawa 101
Naples 90
Dong Ket 84
Redondo Beach 82
Tokyo 72
Council Bluffs 70
Napoli 70
São Paulo 67
Buffalo 63
Munich 49
Haiphong 47
Lawrence 46
Da Nang 43
Wilmington 42
Orem 41
Jacksonville 40
Shenyang 38
Seattle 34
Dallas 31
Mexico City 29
Nanchang 29
Frankfurt am Main 28
Seoul 27
Brooklyn 26
Hebei 26
Tianjin 26
Montreal 25
Nuremberg 25
Rio de Janeiro 25
Chicago 24
Milan 24
Denver 22
Atlanta 21
Baghdad 21
Chennai 21
Helsinki 21
Pasadena 21
Stockholm 21
Rome 20
Houston 19
Hải Dương 19
London 19
Turku 19
Jiaxing 18
Changsha 16
Toronto 16
Ann Arbor 15
Brasília 15
Falkenstein 15
Warsaw 15
Bar Harbor 14
Biên Hòa 13
Johannesburg 13
Redwood City 13
Woodbridge 13
Charlotte 12
Guangzhou 12
Nairobi 12
Philadelphia 12
Quito 12
Belo Horizonte 11
New Delhi 11
Ninh Bình 11
Salvador 11
Baku 10
Bangkok 10
Manchester 10
Poplar 10
San Francisco 10
Sorocaba 10
Vienna 10
Can Tho 9
Curitiba 9
Guayaquil 9
Lahore 9
Mumbai 9
Shanghai 9
Norwalk 8
Phoenix 8
Totale 8.204
Salva come PNG Salva come JPEG
Nome #
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial 286
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 226
New perspectives on the use of nucleic acids in pharmacological applications: inhibitory action of extracellular self-DNA in biological systems 182
(Auto-)immune signature in aplastic anemia 176
Eculizumab treatment modifies the immune profile of PNH patients. 173
Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey 170
Narrative Based Medicine as a tool for needs assessment of patients undergoing hematopoietic stem cell transplantation 166
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for proximal complement inhibition? A position paper from the SAAWP of the EBMT 157
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 156
Eltrombopag for post-transplant cytopenias due to poor graft function 156
ALEMTUZUMAB FOR APLASTIC ANEMIA AND RELATED IMMUNE-MEDIATED BONE MARROW FAILURES: LONG-TERM FOLLOW UP OF A PILOT STUDY 146
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia 141
XM02 PLUS CHEMOTHERAPY IS SAFE AND EFFECTIVE IN STEM CELL MOBILIZATION FOR PATIENTS CANDIDATED TO AUTOLOGOUS STEM CELL TRANSPLANTATION 141
LONG-TERM FOLLOW UP OF ALENTUZUMAB-BASED IMMUNOSUPPRESSION FOR THE TREATMENT OF IMMUNE-MEDIATED BONE MARROW FAILURE SYNDROMES 139
Acute immune toxicity during anti-thymocyte globulin: That's CARPA! 139
Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. 137
PEG-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : A SINGLE-CENTRE EXPERIENCE 133
Twenty years of the Italian Fanconi Anemia Registry: Where we stand and what remains to be learned 133
PEGYLATED-FILGRASTIM AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION: SINGLE CENTRE EXPERIENCE 132
Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. 131
THIOTEPA AND MELPHALAN AS NEW CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE LYELOMA 131
Oral dysplastic complications after HSCT: Single case series of multidisciplinary evaluation of 80 patients 131
CIRCULATING MEGAKARYOCYTE-DERIVED CELLS DETECTED BY FLOW CYTOMETRY AS MARKER OF AGGRESSIVE NEOPLASM OF MEGAKARYOCYTIC LINEAGE IN ACUTE MEGAKARYOBLASTIC LEUKEMIA AND ALLIED MALIGNANCIES PRESENTING AS PRIMARY MYELOFIBROSIS 130
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study 130
Transplant results in adults with Fanconi anaemia 128
Retroperitoneal extramedullary relapse after blinatumomab in acute lymphoblastic leukemia failing haplo-identical bone marrow transplantation. 126
Paroxysmal Nocturnal Hemoglobinuria: significant association with specific HLA-A, B, C and DR alleles in Italian patients 125
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future 124
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients 123
Killer Immunoglobulin-like Receptors (KIR) and their HLA-ligands in Italian Paroxysmal Nocturnal Haemoglobinuria (PNH) patients 123
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 119
Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. 119
Long-lasting bone damage detected by dual-energy x-ray absorptiometry,phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation 118
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 116
Network references for rare diseases: state of the art for the paroxysmal nocturnal hemoglobinuria 115
CHRONIC GRAFT Vs HOST DISEASE OF THE GENITAL TRACT: DIAGNOSIS, CLINICAL IMPACT AND MANAGEMENT FROM SURVEILLANCE PROGRAM IN A PRELIMINARY COHORT 114
Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule 112
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. 110
Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group 110
Bone Marrow of Contention: A Rare Case of Recurrent Acute Hepatitis 110
Antilymphocyte globulin for prevention of chronic graft-versus-host disease 108
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions 107
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria 106
Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls 105
Epidemiology of Acquired Bone Marrow Failure 105
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 105
Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group 105
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. 104
Expression of the 67-kDa laminin receptor in acute myeloid leukemia cells mediates adhesion to laminin and is frequently associated with monocytic differentiation. 102
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High Dose Cyclophosphamide 102
CD34+ cells from Paroxysmal Nocturnal Hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrPc). 101
Aplastic anemia: immunosuppression. Current challenges and future goals in immunosuppression for aplastic anemia. 100
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target 99
Role of the Urokinase Receptor (uPaR) in the cross-talk of hematopoietic Stem Cells with the bone marrow environment 98
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 95
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study 94
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. 93
T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. 93
Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. 92
Easy genotyping of complement C3 'slow' and 'fast' allotypes by tetra-primer amplification refractory mutation system PCR. 91
Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties 91
Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal hemoglobinuria. 90
Immunological derangement in hypocellular myelodysplastic syndromes. 90
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. 86
New challenges to developing animal models for human immune-mediated marrow failure. 85
Allogeneic stem cell transplantation for acquired pure red cell aplasia 85
Shared And Individual Specificities Of Immunodominant Cytotoxic T Cell Clones In Paroxysmal Nocturnal Hemoglobinuria As Determined By Molecular Analysis. 84
Retrospective survey on the prevalence and outcome of prior autoimmune diseases in patients with aplastic anemia reported to the registry of the European group for blood and marrow transplantation. 84
Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab). 84
PNH and eculizumab. 82
A pilot study of the recombinant soluble human tumor necrosis factor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. 82
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: A retrospective analysis 82
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies 82
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the gruppo italiano trapianto midollo osseo (GITMO) 78
Aplastic anemia: management of adult patients. 77
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial 76
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial 76
Multi-center experience using total lymphoid irradiation and anti-thymocyte globulin as conditioning for allografting in hematological malignancies. 75
Paroxysmal nocturnal hemoglobinuria and other complement-mediated haematological disorders. Immunobiology. 75
Long-lasting bone damage detected by dual-energy x-ray absorptiometry,phalangeal osteosonogrammetry,and in vitro growth of marrow strmal cells after allogeneic stem cell 74
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010 Meeting Report. 74
The relationship of aplastic anemia and PNH. 74
Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. 74
The european hematology association roadmap for european hematology research: A consensus document. 74
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria 74
Paroxysmal Nocturnal Hemoglobinuria: The Future Of Complement-Based Therapies 73
Advances in understanding the pathogenesis of acquired aplastic anaemia 73
Long lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant 72
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. 72
Pegcetacoplan versus Eculizumab in PNH. Reply 71
Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation 70
Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment 70
Stem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantation 70
Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. 69
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anemia and single-lineage marrow failure: a pilot study and a survey from EBMT WPSAA. 69
Therapeutic complement modulation for hematological diseases: Where we stand and where we are going 69
Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: A Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation 69
Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab 69
Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria 68
Aplastic anemia: immunosuppressive therapy in 2010. 68
Totale 10.699
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.751
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.751
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022816 2 1 2 1 3 26 7 42 96 42 151 443
2022/2023911 191 79 18 33 106 97 9 107 128 90 44 9
2023/2024601 10 107 108 26 27 43 8 52 8 9 153 50
2024/20254.172 246 241 15 37 60 153 506 264 430 449 1.412 359
2025/20268.042 878 654 699 750 1.234 339 851 525 1.199 551 176 186
2026/2027119 119 0 0 0 0 0 0 0 0 0 0 0
Totale 15.840